Popular TV and Blog Healthcare Expert Joins Pioneer in Early Breast Cancer Detection

Reno, Nev. – March 18, 2014 – First Warning Systems, Inc. (FWS), a digital health, wearable body media and large data company for early breast cancer detection, announced it has appointed Barb Dehn, RN, MS, NP to the company’s Clinical Advisory Board. Known as “Nurse Barb” to legions of her television and blog followers, Dehn is the host of Nurse Barb’s Daily Dose which is broadcast throughout the country on ABC and The Live Well Network. She is a practicing women’s health nurse practitioner, award winning author and a nationally recognized health expert.
“It is a great honor to have Barb Dehn join our team as a key member of our Clinical Advisory Board,” said Rob Royea, president and CEO of FWS. “She is a highly regarded healthcare expert with extensive experience in women’s health. Her credibility and medical insights have truly led to her being recognized as America’s Leading Nurse Practitioner.”
Dehn holds a BS from Boston College and earned her masters degree at the University of California, San Francisco. An in-demand and popular national speaker on all aspects of women’s health, she also lectures at Stanford and is a go-to health expert on television. She has appeared on CBS, CNN, Good Morning America Now and NBC’s iVillageLive. Nurse Barb’s first book, A Hot Guide to a Cool, Sexy Menopause (Basic Health Publications) is being released in May 2014.
“Women are in great need of new technology, such as First Warning Systems’, as we continue our efforts to bolster early breast cancer detection,” said Dehn. “This affordable and convenient FWS BodyMedia technology could provide a significant step towards meeting this goal. I am pleased to be a part of this endeavor and look forward to help introduce this innovative concept to patients and clinicians worldwide.”
This BioMedia system uses a small data collection device placed under a bra to collect 2-12 hours of breast cell data (dynamic cell chaos). Circadian rhythm-based temperature variances of cell cycles are then measured through a patented process to identify abnormalities at the earliest stages of cell augmentation, the results of which are transferred through a smart device to a global cancer library.
“More than 296,000 women in the U.S. are diagnosed with breast cancer annually and approximately 39,000 die from the disease each year, many due to lack of early detection,” said Dehn.  “Contributing factors can be due to dense breast tissue which masks cancer on mammograms for women of all ages, but especially those under 40. In addition, many women have lack of access to healthcare centers and many have genetic or family history of the disease, but are challenged by mammography diagnosis limitations.”
With extensive clinical trials, and years of advanced algorithm refinement completed, FWS’ patented intelligent predictive models are projected to improve accuracy for breast cancer assessment to over 75 percent.  Unlike mammography and ultrasound, which image tissue characteristics, the FWS system measures tissue alterations at the cellular level allowing for early, safe, and accurate cancer prediction for women of all ages and tissue types.  Ultimately, the FWS system is intended to reduce the number of potentially unnecessary biopsy procedures, while refining the need for surgeries.

About First Warning Systems Process

Dynamic thermal readings of breast tissue cellular changes creates a patented time sequenced profile which correlates to circadian cellular processes expressed through specific circadian genotypes. Multiple bioinformatics algorithms compare the circadian gene expression profiles to identify breast tissue abnormalities at different stages of development of disturbed breast tissue cells. FWS delivers an objective Clinical Decision Support Service report to the primary care physician with industry leading accuracy.

About First Warning Systems

First Warning Systems, (FWS) founded in 2008, is based in Reno, Nev. The FWS product line is a device and software service that detects breast tissue abnormalities leading to health risk assessment and management including early breast cancer identification. Three clinical trials with over 500 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. FWS’ technology is exclusively licensed for development, manufacturing and marketing worldwide from Lifeline Biotechnologies, Inc (OTC Market: LLBO). FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS is preparing to apply for a Euro CE Mark to market in the European Union and Asia Pacific markets. See FWS’ video, “Breast Cancer Tumor Progression” at

Media Contact:

Laurie Hallwyler